Research Analysts Set Expectations for BCRX Q2 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - HC Wainwright increased their Q2 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.10 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $1.29 EPS.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 target price (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Price Performance

BCRX traded up $0.06 on Thursday, hitting $9.98. 7,606,302 shares of the stock were exchanged, compared to its average volume of 2,989,382. BioCryst Pharmaceuticals has a 12 month low of $5.34 and a 12 month high of $11.11. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -16.36 and a beta of 1.08. The business has a 50-day moving average of $7.87 and a two-hundred day moving average of $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the firm posted $0.28 earnings per share. The company's revenue was up 40.8% compared to the same quarter last year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in BCRX. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the period. Eversept Partners LP lifted its position in BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after acquiring an additional 1,444,907 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after buying an additional 971,040 shares during the last quarter. Hillsdale Investment Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 65,213.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock worth $4,077,000 after purchasing an additional 541,270 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $3,983,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.